ISTH DIC subcommittee communication on anticoagulation in COVID-19

Jecko Thachil, Nicole P. Juffermans, Marco Ranucci, Jean M. Connors, Theodore E. Warkentin, Thomas L. Ortel, Marcel Levi, Toshiaki Iba, Jerrold H. Levy

Research output: Contribution to journalArticlepeer-review


Hypercoagulability is an increasingly recognized complication of SARS-CoV-2 infection. As such, anticoagulation has become part and parcel of comprehensive COVID-19 management. However, several uncertainties exist in this area, including the appropriate type and dose of heparin. In addition, special patient populations, including those with high body mass index and renal impairment, require special consideration. Although the current evidence is still insufficient, we provide a pragmatic approach to anticoagulation in COVID-19, but stress the need for further trials in this area.

Original languageEnglish
Pages (from-to)2138-2144
Number of pages7
JournalJournal of Thrombosis and Haemostasis
Issue number9
Publication statusPublished - Sep 1 2020


  • anticoagulant
  • coagulopathy
  • Covid-19
  • D-dimer
  • prothrombin time

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'ISTH DIC subcommittee communication on anticoagulation in COVID-19'. Together they form a unique fingerprint.

Cite this